Vitamin A and D Supplementation in Allogeneic HCT

Recruiting Phase 2 Interventional Study
Acute Lymphoblastic Leukemia Acute Myeloid Leukemia Biphenotypic Acute Leukemia Lymphoblastic Lymphoma Chronic Myeloid Leukemia Myelodysplastic Syndromes Myeloprolipherative Neoplsm Non-hodgkin Lymphoma
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Trial phase
Phase 2
Study type
Interventional
Purpose
Treatment
Participants needed
220 (estimated)
Sponsor
St. Petersburg State Pavlov Medical University · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial

The therapy under investigation is the addition of 300 000 IU of vitamin A and 100 000 IU of vitamin D before conditioning. The study will include patients with malignant diseases in hematologic response with indications for allogeneic transplantation with matched related or matched unrelated donor.

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Diagnosis: acute myeloid leukemia, acute lymphoblastic leukemia, myelodysplastic syndrome, chronic myeloproliferative disease, chronic myeloid leukemia, lymphoblastic lymphoma, myeloma * Standard disease risk: less than 5% clonal blasts in the bone marrow and the absence of bl…
Contacts

IVAN SERGEEVICH MOISEEV

+78123386265

moisiv@mail.ru

CONTACT

Irina Сергеевич Bykova

+78123386617

bmt-director@1spbgmu.ru

CONTACT